Day 3: Friday, September 15, 2017

Session 7: Ethics Café 'Are Donor Rights Valuable?'

  Jane Kaye
  Coming soon.
  Evert-Ben van Veen
  Evert-Ben van Veen has worked as a lawyer in health care for most of his career. First at the (then) National Council for Public Health of the Netherlands, then as head legal affairs of what is now the Erasmus Medical Center in Rotterdam, and since 2001 from his Hague-based consultancy firm MedLawconsult and the MLC Foundation. The emphasis is on the ELSI (ethical, legal, and social implications) of public health and observational research alongside hands-on legal advice. The Foundation is the partner in two new European projects, and is also the flag under which Evert-Ben van Veen in particular gives teaching and informational presentations. These are aimed at spreading understanding and inviting consensus on how privacy issues and the need for medical research based on data need not be mutually exclusive. He has been involved in various EU projects for many years. Starting this year he will be the WP leader of the ELSI and governance Work Package of the H2020 RECAP project which aims to combine data from various cohorts to improve the treatment and long term conditions of (very) preterm babies. Evert-Ben also contributed to the yearly proceedings of the Dutch Association for health law with a chapter on ‘big data for a learning health care system’ which was discussed at their annual meeting in March this year.

Session 8A: Establishing Hospital-Based Biobanks as a Foundation for Clinical Trials and Precision Medicine

  Michael H. Roehrl

Dr. Roehrl is a practicing academic pathologist and physician scientist. He is Director of the newly created Precision Pathology Center at Memorial Sloan Kettering Cancer Center. Dr. Roehrl obtained his MD degree from the Technical University of Munich, Germany, and holds a PhD in Biological Chemistry from Harvard University.

Dr. Roehrl trained at Massachusetts General Hospital in Boston and is dually board-certified in both anatomic pathology and laboratory medicine. Dr. Roehrl has held faculty positions in Boston and Toronto before moving to his current position in New York. Dr. Roehrl's research lab focuses on biomarker discovery in solid tumors, in particular, colorectal and pancreatic cancer, using a variety of biochemical, biophysical (mass spectrometry), and computational approaches. In 2017, Dr. Roehrl became site PI for the NCI CPTAC proteogenomics consortium.

  Stefan Holdenrieder
  Prof. Stefan Holdenrieder is Director of the Institute of Laboratory Medicine at the German Heart Center (DHM) of the Technical University Munich (Germany). At the DHM he has established a Biomarker Center and a Biofluid Biobank that is part of the Joint Munich Biobank (JMB). Being a specialist in laboratory medicine, his research interests are the development and comprehensive validation of new biomarkers and technologies for diagnostic applications in cardiology, oncology, immunology, neurology, and pediatrics. His special focus is spot on circulating cell-free nucleic acids, their genetic and epigenetic modifications, (exosomal) miRNA, protein and metabolomics markers as well as the development of multiparametric algorithms. His laboratory has been part of many international multicentric biomarker evaluation studies and serves as a diagnostic center for the Central European Society of Anticancer Drug Research (CESAR). Prof. Holdenrieder is secretary of the International Society of Oncological BioMarkers (ISOBM), EQA consultant for tumor marker ring trials at Instand e.V. and associate editor of several international journals.
  Núria Somoza
  Núria Somoza is technical manager in MARBiobanc (the Parc de Salut Mar’s biobank). She received her PhD in cellular and molecular characterization of recent onset insulin-dependent diabetes mellitus. After that she was involved in core facilities (flow cytometry and cell sorting) for two years. She has also work as a technical manager in an in vitro diagnostic company. Núria joined the Parc de Salut Mar in 2006 to take responsibility in the cryopreservation unit. Currently she is involved managing the donors informed consents and the sample requests.
  Martina Oberländer
  Coming soon
  Beatriz Martínez Gálvez

Biobank technician at Málaga Provincial Node of the Andalusian Biobank. She is an anatomic pathological technician, currently studying environmental grade.

She has years of experience at the biobank and one more as research supporter in histology and animal cabinet at the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND).
She has also taken part in scientific advisory activities like open days and the European Researcher’s Night.

Currently, her work at the biobank consists in research support in processing and transfer of liquid and solid biological samples, in different formats.

She also developed the management of healthcare archive samples for the oncological clinical trial system in Andalusia.

She has several contributions in national and international congress and now she is working on an article of great interest about this work performed, which will be sent to a journal index in the JCR.

  Ayat Salman
  Coming soon.

Session 8B: Big Data and Large Population Research - From Cohorts to Health Care

  Mine Cicek
  Dr. Mine Cicek received her PhD in Genetics from Virginia Tech, Blacksburg, VA in 2001. Following a postdoctoral research fellowship at the Cleveland Clinic, Lerner Research Institute, she came to Mayo Clinic, Rochester, Minnesota in 2005 as a R25 Cancer Genetic Molecular Epidemiology Fellow. After completion of her training, she then worked in the capacity as a research associate in the Division of Experimental Pathology and Laboratory Medicine from 2006-2010, then the Division of Epidemiology, Department of Health Sciences Research from 2010-2013. She is trained as a lab-based researcher in the cancer genetic epidemiology field and has worked on multiple tumour types. She has led and published multiple studies with similar research goals on prostate, colon and ovarian cancer genetics. In 2013, she accepted the position as the laboratory director of the Biospecimens Accessioning and Processing (BAP) core laboratory, Biorepository Program, and Center for Individualized Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Cicek presently is an Assistant Professor of Laboratory Medicine and Pathology in the Mayo Clinic College of Medicine and is a Senior Associate Consultant at the Mayo Clinic, Rochester, Minnesota. Her main focus is to contribute her expertise in research studies and clinical trials overseeing biospecimen collections, processing and storage. Dr. Cicek continuously tries to bring new knowledge and technology to her lab to improve on quality and best practices for biospecimens usage in biobanking. She is Mayo Clinic PI of The Alliance NCTN Biorepository and Biospecimen Resource. She is Co-PI of the Precision Medicine Initiative (PMI) All of Us (AoU) Research Program Biobank.
  Chen-Yang Shen
  Prof. Chen-Yang Shen currently is a research fellow/professor in Academia Sinica. During his academic career, he was appointed as the deputy director of the Institute of Biomedical Sciences, Academia Sinica (2011-2013). Since 2005, he has been involved in the Taiwan Biobank, a national project aiming at the establishment of national cohorts of chronic diseases in Taiwan, and he is now the Chief Executive of Taiwan Biobank (since 2008). Currently, Prof. Shen also serves as the President of the Taiwan Epidemiology Association. Prof. Shen has dedicated himself to molecular and genomic epidemiological research on breast cancer for 25 years. His discoveries of multiple breast cancer susceptibility genes have resulted in the invitation, made by one of the most active international consortium of breast cancer research in the world (i.e. the Breast Cancer Association Consortium) to Prof. Shen’s lab, and joint publication of more than 25 papers in the field of genome-wide association study of breast cancer. Furthermore, Prof. Shen has been known as an expert of DNA repair. He has identified novel interactions between different DNA checkpoint/repair mechanisms, and the signalling pathway to explain breast tumorigenic contribution of the fibroblast growth factor. Recently, Prof. Shen has attempted to translate his academic works into public health practice and personalised medicine. In two publications in NEJM (2011) and BMJ (2015), he led Taiwanese teams to demonstrate the clinical feasibility to prevent adverse drug reaction by pre-screening specific HLA alleles of patients. These two studies have been considered excellent examples of precision medicine.
  Nazneen Aziz
  Dr. Aziz is the executive director of the Kaiser Permanente Research Bank. Dr. Aziz’s interest and expertise is in the implementation of genomics in clinical practice. In her previous roles, Dr. Aziz was the director of molecular medicine at the College of American Pathologists where she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz has held executive leadership positions in biotech and healthcare including most recently as the SVP/chief research officer at Phoenix Children’s Hospital. Nazneen was an assistant professor at Harvard Medical School and Boston Children's Hospital and now holds a research professorship title in the School of Life Sciences at Arizona State University. Nazneen received her PhD in molecular genetics at MIT. She is on the National Academies Round Table of Genomics and Precision Health and the US Government Accountability Office’s expert panel on multiplex technologies.
  Marian Beekman
  Marian Beekman (1972) was trained as a biomedical scientist and studies the role of genetic and phenotypic variation in human healthy ageing and longevity. Her research is focused on identifying variation in genomic regions that contribute to metabolic health and longevity, where variation in gene expression, DNA sequence, and methylation marks are of interest. Integration of genetic data with a wide scale of omics data to investigate how genetic variation can contribute to healthy ageing is one of the major goals in her studies. Therefore, she combines the in-depth phenotyping of the participants of the Leiden Longevity Study (Leiden LangLeven Studie) with the data analysis in the setting of molecular epidemiology.
  Hakim Achterberg
As of December 2013, Hakim is working as a scientific programmer in the BIGR group at the Erasmus Medical Center in Rotterdam, where he focuses on the IT infrastructure for large imaging studies (e.g. The Rotterdam Scan Study, including over 12.000 MR sessions). This includes creating software for the management, storage, transfer, processing, and annotation of large imaging dataset. For processing both automated pipelines as well as integrated annotation tools are used.

Hakim is the main developer for a number of tools, including the open-source workflow engine Fastr and the python XNAT communication package xnatpy.

  Kaisa Silander

Kaisa Silander, PhD, is currently the development manager and deputy director of THL Biobank in Helsinki, Finland. Her main responsibility is the utilisation of THL Biobank’s samples and data for research purposes, including the biobank’s availability services, research application process, harmonisation of cohort data, and biobank registries. She takes part in BBMRI-ERIC’s Common Service IT activities, leading the work package for the development of harmonisation tools for biobank data. In addition to her work at the CoCoBi project presented here, she is also involved in’s Isaacus Project (Finnish Biobanks’ joint Service Operator pilot).

Kaisa obtained her doctorate in medical genetics from the University of Turku in 1998, has been a postdoc at the laboratory of Francis Collins at the National Human Genome Research Institute, USA, between 1998 and 2002, and later head of genetic laboratory for the late Professor Leena Peltonen-Palotie at THL and FIMM. She has an extensive background in molecular genetic laboratory methods and research into complex genetic diseases

Session 8C: Reproducibility of Data from Specimens – Quality and Heterogeneity from Original Pathology to Derived Source

  Too Heng Phon
Dr. Too Heng Phon received his undergraduate training in Biochemistry, Imperial College of Science & Technology, UK. He then continued with his PhD training in a joint research project at Imperial College, Institute of Ophthalmology and West Minister Hospital, London. Thereafter, he received further training with the Medical Research Council, Cambridge (UK), where he was a Procter & Gamble Fellow. He then moved to the Department of Anesthesiology and Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School where he was a recipient of the Merck Sharpe Dohme Academic Development Fellowship. Currently, he is a faculty member in the Department of Biochemistry, National University Singapore, an Adjunct Scientist in the Bioprocess Technological Institute, and a Fellow of the Singapore Massachusetts Institute of Technology Alliance (Molecular Engineering of Biological & Chemical Systems program; Chemical & Pharmaceutical Engineering program). Dr. Too is a molecular biologist focusing on biotechnology and neuroscience. In recent years, Roche Diagnostics (USA & Asia Pacific) and the National Institute of Health (USA) funded him to develop qPCR assays for infectious diseases. He is an awardee of a number of commercialization of technology grants from A*STAR and Singapore-Massachusetts Research & Technology (SMART). Dr. Too has collaborated on the co-development of IVD for prognostic/diagnostic for breast cancer. He is the founder of MiRXES in Singapore. He has intellectual property protections on specific diagnostic platforms with various research departments and with Massachusetts Institute of Technology, USA.
  Matilde Valeria Ursini


Dr. Matilde Valeria Ursini is group leader of Human Molecular Genetics laboratory at the Institute of Genetics and Biophysics of the National Research Council in Italy and professor of Human Genetics. Most of her scientific activity has been dedicated to the discovery of the genetic basis of the rare human diseases and in the more recent years she focused her research to the study of the Incontinentia pigmenti rare disease with a classical genetic approach coupled to an innovative precision medicine approach to investigate on the pathophysiology of severe aspect of this disease. In this field she has published more then 50 papers in the last 15 years and has patented a one-step kit for IP molecular diagnosis.

This activity has made dr. Ursini a reference partner in a large network of scientific and personal interactions with clinicians and with patient associations belonging to the “Incontinentia Pigmenti community” all over the world. Thanks to this activity she has contribute at the establishment of the first and the only Incontinentia Pigmenti Genetic Biobank of the BBMRI of which she is Biobank Deputy Director (

Dr. Ursini is a biologist and she has worked in the field of genetics since years 90’ at the University Lyon I in France and at the NIH in WA DC before to became a full researcher and group leader at the IGB-CNR.

  Heather Thorne
  With a background in laboratory research in the molecular genetics of breast cancer, Heather was appointed the first national manager of kConFab, the Australasian research consortium for families at high risk of breast, ovarian, and prostate cancer. She has managed all project logistics, supervised staff and ethics submissions to recruit participants/families at 32 Australasian sites, established protocols for the biospecimen and data bank and overseen the distribution of and associated data to 165 approved national and international projects involving 300+ researchers that span psychosocial research through to basic science. She is particularly interested in expanding upon a biobanks/cohorts translational role by supplying directly to participants, their families and their treating clinicians in the National Family Cancer Clinics clinically significant mutation test and assisting to recruit eligible participants to new targeted therapies based on their gene profile for either germ-line or somatic mutations.
  Rita Theresa Lawlor
  Coming soon.

Session 9A: Biobank Catalogues - Technical Operations

  Philip Quinlan
  Dr. Philip Quinlan has developed a career in data systems for biomedical research and is currently the Chief Technology Officer at the Advanced Data Analysis Centre (ADAC) at the University of Nottingham. ADAC provides data analytical expertise to the research and commercial sectors as a core service within the University. A flagship project of ADAC is to provide the leadership of the UKCRC Tissue Directory and Coordination Centre ( and Dr. Quinlan is the Director. The main output from this project is the development of the UKs first tissue directory that is cross-disease and also is a requirement of favourable ethical permission. Dr. Quinlan has become the Director of the UKCRC Tissue Directory and Coordination Centre having worked on database and operational systems to support biobanks since his graduation in Applied Computing in 2004. His current interest is in understanding and developing strategies for biobanks to respond to increasing data-oriented requirements.
  Horst Pichler
  Dr. Horst Pichler is engaged in (Biobanking and BioMolecular resources Research Infrastructure Austria) and deals with problems of standardisation and harmonisation of data management in biobanks. After his PhD in technical sciences he specialised on different aspects of systems integration, participated in several national and international research projects, authored many international publications, consulted large integration projects, managed development teams, and helped shaping applications to readiness for market.
  Joanne Demchok
  Joanne earned her Masters of Science through the University of Maryland at Baltimore, specialising in biomedical research. Previously she worked at NIH’s pediatric oncology branch where she focused on developing experimental assays to implement new strategies for the diagnosis, treatment, and prevention of fungal infections in immunocompromised patients. Presently she serves as program director managing the Cooperative Human Tissue Network grants and The Specimen Resource Locator.
  Oliver Karch
  Coming soon.
  Ny Haingo Andrianarisoa
  Ny Haingo Andrianarisoa joined the International Agency for Research on Cancer (IARC) in early 2015 as research assistant of the laboratory services and biobank group. He deals with analysis and development of workflows and IT tools for samples management at IARC. He is also in charge of advising and supporting all IT aspects of the Biobank and Cohort Building Network (BCNet) of LMICs, which is coordinated by IARC. As a French research fellow in the LIRIS lab hosted in the National Institute for Applied Sciences (Lyon, France), he worked on data access and integration for combining database federation and grid computing. He then served as the IT manager of Remera, the French main registry for birth defects, covering the Rhone-Alps region. In addition, he holds a position of assistant professor in computer science at the University of Lyon, France.

Session 9B: Linking Human Biomonitoring and Population-Based Health Studies

  Antonia M. Calafat
Antonia Calafat is the Chief of the Organic Analytical Toxicology Branch at the Division of Laboratory Sciences, National Center for Environmental Health of the US Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. She earned her Bachelor, Master, and Doctoral degrees in Chemistry from the University of the Balearic Islands (Spain). Prior to her career at CDC, she was a Fulbright Scholar and a Research Associate at Emory University. She currently leads CDC’s biomonitoring programs for assessing human exposure to pesticides; polycyclic aromatic hydrocarbons; flame retardants; persistent organic pollutants such as per- and poly-fluoroalkyl substances; polybrominated diphenyl ethers; and polychlorinated dibenzo-p-dioxins, furans, and biphenyls; and chemicals added to consumer and personal-care products such as phthalates and phenols (e.g., bisphenol A, triclosan, parabens). Antonia has developed and maintained extensive collaborative research with leading scientists in the fields of exposure science, epidemiology, toxicology, and health assessment, and has co-authored more than 350 peer-reviewed publications. Her research has made relevant contributions to CDC’s biomonitoring program including the CDC’s National Reports on Human Exposure to Environmental Chemicals.
  Marike Kolossa-Gehring
  Marike Kolossa-Gehring, Head of Section “Toxicology, Health-related Environmental Monitoring”, German Environment Agency, Germany HBM4EU coordinator. She got her PhD from the Christian-Albrechts-University Kiel. In the German Environment Agency she is in charge of the scientific lead and management of the German Human Biomonitoring Program (German Environmental Survey GerES, the German Environmental Specimen Bank ESB, the German Human Biomonitoring Commission, and the HBM cooperation between the German Chemical Industry Association (VCI) and the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB)). She was involved in the development of assessment strategies and guidelines at the national, EU and OECD level and from 2006 to 2010 vice-chair and chair of the OECD Endocrine Disruptor and Assessment Task Force. She was work package leader in the EU HBM projects ESBIO, DEMOCOPHES and COPHES, the Consortium to Perform Human Biomonitoring on a European Scale preparing and piloting a European human biomonitoring study. From 2011 to 2014 Governmental Councillor of the International Society of Exposure Science (ISES).
  Nadine Volk

Kynast, K.L., Volk, N., Fleming, T.H., Herpel, E. (2017). Diabetes-Associated Biobanking: More Topical Than Ever? Experimental and Clinical Endocrinology & Diabetes. accepted

Hidmark, A., Spanidis, I., Fleming, T.H., Volk, N., Eckstein, V., Groener, J.B., Kopf, S., Nawroth, P.P., and Oikonomou, D. (2017). Electrical Muscle Stimulation Induces an Increase of VEGFR2 on Circulating Hematopoietic Stem Cells in Patients With Diabetes. Clinical Therapeutics 39, 1132–1144.e2.

Mendler, M., Riedinger, C., Schlotterer, A., Volk, N., Fleming, T., Herzig, S., Nawroth, P.P., and Morcos, M. (2016). Reduction in ins-7 gene expression in non-neuronal cells of high glucose exposed Caenorhabditis elegans protects from reactive metabolites, preserves neuronal structure and head motility, and prolongs lifespan. Journal of Diabetes and Its Complications.

Micakovic, T., Papagiannarou, M., Clark, E., Volk, N., Fleming, T., Gröne, H., and Hoffmann, S. (2016). Angiotensin II type 2 receptor (AT2R) localizes to mitochondria of renal tubules and modifies mitochondrial function in early stages of type 1 diabetes in rats. Diabetologie und Stoffwechsel 11.

Volk, N., Fleming, T., Kliemank, E., and Nawroth, P. (2015). Organ-specific effects of diabetes on mitochondrial function. Diabetologie und Stoffwechsel 10.

  Ana Virgolino

Ana Virgolino is a clinical and health psychologist currently working as a research fellow in the faculty of medicine at the University of Lisbon. She has also been collaborating with the Institute of Preventive Medicine and Public Health and with the Institute of Environmental Health of the same faculty since 2013.

Over the last few years, Ana has collaborated on several scientific projects in the areas of public, environmental and mental health, epidemiology, aging, and sexuality and gender, with various publications in these fields.

Before her work with the faculty of medicine, Ana was engaged in clinical practice of psychology, collaborating with several community services.

  Liv Paltiel
  Coming soon.

Session 9C: Biospecimen Evidence-Based Practices for Collecting and Utilizing FFPE Tissues

  Helen Moore
Dr. Helen Moore leads the NCI Biorepositories and Biospecimen Research Branch (BBRB). As Chief she sets the direction and strategic vision for the Branch and oversees a complex set of projects related to biobanking, including: The NCI Best Practices for Biospecimen Resources, a foundational document for biobanking in use internationally; a biospecimen science research program to develop the evidence for biospecimen best practices; the Biospecimen Research Database, a web-based biospecimen science literature database; research in the ethical, legal, and social implications of biobanking; and biobanking operations for major NCI and NIH programs including the NIH Genotype-Tissue Expression (GTEx) Program. Dr. Moore previously led BBRB's Biospecimen Research Network (BRN). She speaks internationally about BBRB and biobanking, publishes articles related to BBRB and related initiatives, and serves as expert reviewer and member of advisory boards. Dr. Moore is a molecular biologist with a broad background in research and development. She came to the NCI from Celera Genomics. Dr. Moore earned her doctorate at Cornell University and her BA at Wellesley College.
  Fay Betsou
  Dr. Betsou is Chief Scientific Officer at Integrated Biobank of Luxembourg (IBBL), where she directs activities of the Biorefinery and Biospecimen Research Laboratory. She is a molecular biologist with 20 years of experience in molecular diagnostics, disease-oriented biobanking, biospecimen research, and certification and accreditation applied to biobanks. She holds four patents and is the author of more than 90 peer-reviewed publications, most focused on biospecimen research. She is a Past President of International Society for Biological and Environmental Repositories (ISBER), and Chair of the ISBER Biospecimen Science Working Group and the Proficiency Testing Taskforce. She is a national delegate in ISO REMCO and ISO TC276, and an Associate Professor at the University of Luxembourg.
  Rocío Aguilar Quesada

Rocío has been working as head of the laboratory in the Andalusian Public Health System Biobank in Granada since 2009. She received her Master degree in biobanking and use of human samples in biomedical research organised by both the Catholic Valencia University and the Spanish National Biobank Network. Rocío is currently participating in different research projects and working groups with scientific publications in progress.

Previously, Rocío was working as a postdoctoral researcher in the Institute of Parasitology and Biomedicine "López-Neyra" from the Spanish National Research Council, after receiving a Master in molecular and cellular immunology and a european PhD degree in biochemistry on molecular oncology, both from the University of Granada. She performed part of her thesis in the Genome Damage and Stability Centre (Brighton, UK), the Institute of Signaling, Developmental Biology and Cancer Research (Nice, France) and the Institute for Biomedical Research “Alberto Sols“ (Madrid, Spain).

  Laurent Dollé

Laurent Dollé earned his PhD degree in cell biology and life sciences from the University of Science and Technologies of Lille (France) in 2003. Laurent joined then the group of Professor Marc Mareel from the University of Gent in Belgium to become specialist in breast cancer cell invasion and metastasis processes. After several positions at different Universities or Institutions of Belgium, Laurent has over 16 years of experience working in the life sciences field. In 2012, Laurent became assistant professor at the Free University of Brussels VUB), and developed several skills in stem cells isolation, maintenance, and differentiation and was the first to identify liver stem cells from healthy non-manipulated livers by playing with an innovative technique based on aldehyde dehydrogenase.

Laurent Dollé is currently the operating director of BWB (Biobanking Wallonia-Brussels; Belgium), which regroups an impressive number of biobanks whose mission is to create and implement a virtual network to unify and make accessible human materials and associated data managed by the biobanks of Wallonia-Brussels’ territory. BWB’s services benefit to big pharma, pharmaceutical, biotech, in vitro diagnostics and big data companies, and academia. The task is to support biomedical research for the benefit of patients by providing high-quality specimens - among others: blood, sera, tissues (fresh, frozen or FFEP), urine, saliva...- and associated medical and biomolecular data compliant with international quality standards and regulations - so they can be used in a truthful and reproducible manner to leverage your research or to pursue the development of your in vitro diagnostic or laboratory-developed tests peacefully.

Session 10A: Biobank Catalogues – Metrics and Quality

  Petr Holub
Dr. Holub is associate professor of computer science at Masaryk University. Since 2015, he has become senior IT/data protection manager with BBMRI-ERIC, European Research Infrastructure Consortium for Biobanking and BioMolecular Resources and CIO of BBMRI-ERIC common service IT. He has background both in sciences and computer science. He was head of the dept. of communication technologies at the Institute of Computer Science, Masaryk University, as well as architect of advanced multimedia and collaborative systems of the Czech national e-infrastructure at CESNET. His research in computer networks and multimedia processing has lead to more than 40 research papers in established computer science journals and ranked conferences.
  Kim Vande Loock
  Kim Vande Loock graduated in 2007 as Master in human biology at the Vrije Universiteit Brusse. Afterwards, she started a PhD in the laboratory of cellular genetics at the Vrije Universiteit Brussel focusing on the genetic susceptibility of newborns for DNA damage. This research led to her PhD degree in 2012. In 2013 she started working at the Belgian Cancer Registry, first involved in the PROCARE (Project on Cancer of the Rectum) project and since 2016 as project manager of the Belgian Virtual Tumour Bank.
  Cheryl Gillet

Cheryl Gillett is Head of Biobanking for King’s College London and Manager of the King’s Health Partners Cancer Biobank.

After joining the Guy’s & St Thomas’ NHS Trust Breast Unit, she completed her PhD on proliferative markers in breast cancer and continued with this research whilst developing the breast biobank. In 2006 she joined King’s College London, becoming a Senior Lecturer before Head of Biobanking, in 2010.

A keen advocate of public involvement in developing and supporting research, she oversees a team of volunteers who seek biobank consent and provides researcher support to lay cancer groups at Guy’s Hospital.

Session 10B: The Power of Connections – New Biobanking Networks

  Hugo Alberto Barrera Saldana

Dr. Hugo Alberto Barrera Saldaña is a self-formed biochemist at the Autonomous University of Nuevo León, Mexico with a PhD in biomedicine from the University of Texas, USA and post-doctoral at the University of Louis Pasteur in Strasbourg, France.

He has been a member of the National System of Researchers since its foundation in 1984, and at its highest level since 1996. He is the founder of the UANL research units ULIEG, UDM, and UBM, and the post-graduate degree of the department of biochemistry, the biotechnology course of the biological sicences and the Center for Technology Transfer, as well as the Center and postgraduate in genomic biotechnology of IPN.

Dr. Barrera Saldaña has more than 200 scientific publications and almost 3,000 citations, three books, two patents, has led or codirected a hundred post-graduate theses, and has successful links with companies.

  György Marko-Varga
  Coming Soon
  Jajah Fachiroh
  Jajah Fachiroh, PhD is academic staff in the department of histology and cell biology, faculty of medicine UGM Yogyakarta Indonesia, majoring histology, cell biology, tumor biology, immunology, and molecular epidemiology. She is currently leading the biobank team at the faculty, at the stage of development of Biobank for research, along with development of the tripartit system with two affiliated academic hospitals. She finished her PhD at Vrije Universiteit Amsterdam, The Netherlands majoring in the development of EBV-based biomarkers for nasopharyngeal carcinoma (NPC) diagnosis. She currently manages her research in molecular epidemiology of NPC for the determination of population at risk as part of NPC screening research plan.
  Marianne Henderson
  Ms. Henderson is senior advisor for division resources, division of cancer epidemiology and genetics and senior advisor on biobanking, Center for Global Health of the U.S. NCI. She supports large program and contract management; and infrastructure planning for molecular epidemiology. She is active in the International Society for Biological and Environmental Repositories (ISBER) (ISBER President 2011-12 and current chair of the Organizing Advisory Committee). She is a member of the NIH PMI – CP Biobank working group; and SC member and E&T chair of the IARC-led LMIC Biobank and Cohort Network (BCNet); Ms. Henderson is actively involved in large-scale biospecimen process improvements in operations, technology transfer, sustainability, and repository automation.
  Daniela Fusco
  Dr. Fusco is a molecular biologist with a PhD in virology. She used to work for 10 years at the University of Bologna in basic research with her longest post-doc in human genetics. In 2011 she moved to global health working in different low and middle income countries as implementer of health projects. In this context she also contributed to the development of small operational research projects. Since 2016 Dr. Fusco moved back to research with INSERM (Institut National de la Santé et de la Recherche Médicale) as laboratory specialist for a multi-centric clinical trial rolled out among Guinea, Liberia, and Sierra Leone and promoted by INSERM, NIH and the London School of Hygiene and Tropical Medicine respectively. In this context she came in contact with the field of biobanking due to the importance that is being dedicated to the topic in the aftermath of the last Ebola outbreak.
  Joanna Wójtowicz
  Coming soon.
  Charles W. Wang
  Dr. Charles Wang is a professor with a focus on epigenetic regulation of genes in early development exposed to adverse environmental risk factors. Charles has keen interest in biobank informatics and data management for sharing. Charles earned his MD in China and PhD from M. D. Anderson Cancer Center in USA. Following his postdoctoral training, Charles left Baylor College of Medicine and continued his research at Pfizer. He was recruited specifically to lead a team that conducted disease annotation of rat genome at Wisconsin College of Medicine. After more than a 20-year career living in the USA, Charles decided it was time for a change of scenery. He is recruited specifically by his professional skill set and experience in scientific solutions for biobanking. He has earned his leading role in biobanking science and data management in China. Charles has a large circle of connections both in China and the United States.

Session 10C: Quality Assessment – A Key Factor for Successful Biobanks and Reproducible Science

  Lena Krieger
  Being a project manager at DIN since 2012, Dipl.-Ing. Lena Krieger is the Secretary of ISO Technical Committee 276 "Biotechnology" and its working group “Biobanks and bioresources”; she is also Secretary of the European CEN Technical Committee 140 “In vitro diagnostic medical devices”, and thus responsible for the development of medical and biotechnological standards as well as the coordination of cross-sectorial topics in these areas. She participated in the FP 7 SPIDIA project, is leading the standardisation work package in the European SPIDIA4P Project, and is currently bringing the research results into European and international standardisation.
  Tohru Masui
  Dr. Tohru Masui received his education and training as a developmental biologist at the University of Tokyo. He started his career as a cancer researcher at the Japanese Cancer Research Foundation (JCRF) in 1981. He then moved to the National Cancer Institute in Bethesda, USA for five years to complete his post-doc, returning to JCRF upon completion. In 1995 he moved to the Cellbank at the National Institute of Health Sciences, and was involved in policy and ethics studies on the use of human materials and information in medical research. In 1999 he started to follow the planning process of the UK Biobank and related activities in the UK. He moved to the National Institute of Biomedical Innovation (NIBIO) in 2005 and from 2009, he has been chairing the Department of Bioresources Research (Japanese Collection of Research Biologicals). He also has been working in several areas of governmental committees on bioresource policies and evaluation. He retired from the NIBIO in 2014 and moved to Keio University School of Medicine, the Center for Medical Genetics, as professor. His interest stays in the area of policy and ethics of the use of human materials and information in medical research.
Sabrina Schmitt

Sabrina Schmitt is coordinating the BioMaterialBank in Heidelberg (BMBH). She is member of the QM core team in the German Biobank Node ( and involved in several QM activities of BBMRI-ERIC, member of ISBER and an expert in the working group of the national standardization body DIN, responsible for the biobanking standard ISO 20387.

Her PhD in immunology was followed by a postdoc with three years of research on wound healing mechanisms at the Heidelberg University Hospital. Since 2013, Sabrina Schmitt is involved in biobanking, starting as a quality manager and since this year as the scientific-administrative head of BMBH.

  Peter Riegman
  Peter Riegman is a molecular biologist heading the Erasmus MC Tissue Bank, where fresh frozen tissue and pathology archival FFPE materials for medical research under secondary use is available according to ISO 15189:2012 standards. He was involved in the European projects: EurocanPlatform (WP leader of Biobanks), BIOPOOL, SPIDIA, BBMRI, EuroBoNeT and coordinated the TuBaFrost project 2003-2006. He was co-opted board member and chair of the OECI working group biobanking 2006-2010. In 2008 Peter became ISBER president-elect, and 2009-2010 ISBER president, followed by past president until 2011. At the end of 2010 he was elected vice president of ESBB (ISBER chapter) to become president in 2011, when he also became section editor in the editorial board of Biopreservation and Biobanking and member of the international steering committee of P3G. From 2012 he became UMC-coordinator for the pearl string initiative for Erasmus MC. That same year he joined through NEN the CEN/TC140WG3 and ISO/TC212WG4 to write sample technical standards, now implemented together with BBMRI-ERIC.
  Sabrina Neururer
  Coming soon
  Vincenzo Canzonieri
  Vincenzo Canzonieri received his MD from the School of Medicine at the University of Catania. He attended the residency in anatomic pathology at the University of Padova, in oncology and forensic medicine. He obtained a Mini-MBA in sanitary management at the University Bocconi in Milan. From 1999 to 2004, Dr. Canzonieri worked as a consultant pathologist at the CRO Aviano Cancer Center, National Cancer Institute. From 2005 to 2009, Dr. Canzonieri became responsible of the Aviano Pathology Department and deputy director of the Department of Laboratory Diagnostics and Cell Therapy and, from 2010 to date, he has been responsible for the CRO BioBank. He works as a professor of anatomic pathology at the University of Udine. Dr. Canzonieri is responsible for many approved research projects and has authored numerous scientific articles and participated as invited speaker at many national and international congresses.

Global Biobank Week Closing Ceremony

 Jan-Eric Litton
 Elke Smits
Brent Schacter
 Erik Steinfelder
 Balwir Matharoo-Ball
Zisis Kozlakidis